Managing Childhood Obesity

Required Documents

• Serial height/weight data with BMI trend
• BMI plotted on CDC growth chart (ages 2-20)
• Previous lab results (lipids, glucose, liver enzymes) if available
• Sleep history or polysomnography results if applicable

Step 1 — BMI Classification and Severity

BMI Percentile Categories (CDC, Ages 2-20)

Extended BMI (%95th)

• For children at or above the 95th percentile, express BMI as a percentage of the 95th percentile value for age/sex
• This provides more granularity than raw percentile at the extreme end
• Example: if 95th percentile BMI for a 10-year-old male is 24.0 and the patient's BMI is 30.0, extended BMI = (30.0 / 24.0) × 100 = 125% of 95th → Class II severe obesity

Step 2 — Comorbidity Screening

Required Laboratory Screening (For BMI ≥ 85th Percentile)

Clinical Comorbidity Assessment

• Orthopedic: slipped capital femoral epiphysis (SCFE — hip/knee/groin pain with limping), Blount disease (tibial bowing)
• Pulmonary: obstructive sleep apnea (snoring, daytime somnolence, morning headaches) — polysomnography if symptomatic
• Endocrine: acanthosis nigricans (insulin resistance marker), polycystic ovarian syndrome (PCOS) in females with irregular menses
• Psychological: depression screening (PHQ-A), anxiety, disordered eating behaviors (binge eating), bullying assessment
• Dermatologic: intertrigo, acanthosis nigricans distribution and severity

Step 3 — Staged Intervention Intensity (AAP 2023)

Stage 1: Prevention Plus (All BMI ≥ 85th)

• ≥ 5 servings fruits/vegetables daily
• Minimize or eliminate sugar-sweetened beverages
• Limit screen time to ≤ 2 hours/day recreational (0 for < 2 years)
• ≥ 60 minutes moderate-to-vigorous physical activity daily
• Family meals at table; no eating in front of screens
• Adequate sleep for age

Stage 2: Structured Weight Management (No Improvement After 3-6 Months of Stage 1)

• Structured meal plan with dietitian involvement
• Detailed food and activity logging
• Monthly office visits for weight tracking and behavioral support
• Targeted behavioral goals with family accountability

Stage 3: Comprehensive Multidisciplinary Intervention

• Intensive behavioral therapy (≥ 26 contact hours over 3-12 months)
• Multidisciplinary team: pediatrician, dietitian, behavioral health, exercise specialist
• This is the core treatment recommended by AAP 2023 for children ≥ 6 with obesity
• Where available, Intensive Health Behavior and Lifestyle Treatment (IHBLT) programs

Stage 4: Tertiary Care Intervention

• Pharmacotherapy (age ≥ 12 with obesity, or ≥ 8 per AAP 2023):
  • GLP-1 receptor agonists (liraglutide FDA-approved ≥ 12 years; semaglutide ≥ 12 years)
  • Orlistat (≥ 12 years): limited efficacy, GI side effects
  • Phentermine/topiramate: off-label in adolescents, limited data
  • Setmelanotide: for specific genetic obesity syndromes (MC4R pathway)
• Metabolic and bariatric surgery (age ≥ 13 with Class II obesity + comorbidity OR Class III obesity):
  • Roux-en-Y gastric bypass or vertical sleeve gastrectomy
  • Requires multidisciplinary evaluation, psychological clearance, demonstrated adherence to lifestyle changes
  • Refer to accredited pediatric bariatric center

Step 4 — Motivational Interviewing and Goal Setting

Motivational Interviewing Framework (OARS)

• Open-ended questions: "What concerns do you have about your child's weight?"
• Affirmations: "You're doing a great job by coming to talk about this."
• Reflective listening: "It sounds like it's been hard to find time for physical activity."
• Summarizing: "So you're thinking about reducing soda and adding a family walk after dinner."

SMART Goal Setting (1-2 Goals Per Visit)

• Specific, Measurable, Achievable, Relevant, Time-bound
• Example: "Reduce sugar-sweetened beverages from 3 cans/day to 1 can/day over the next 4 weeks"
• Document goals in chart and review at each follow-up

Weight Trajectory Goals (Not Absolute Weight Loss)

Step 5 — Follow-Up and Escalation

Visit Frequency

• Stage 1: every 3-6 months
• Stage 2: monthly
• Stage 3: weekly to biweekly during intensive phase
• Stage 4: per specialty protocol

Escalation Triggers

• No BMI improvement after 3-6 months at current stage → escalate to next stage
• Development of new comorbidity (T2DM, hypertension, NAFLD) → accelerate staging
• Rapid BMI increase (crossing percentile lines upward) → do not wait standard interval
• Severe obesity (Class II-III) in adolescent → offer pharmacotherapy and Stage 3 simultaneously (AAP 2023)

Checkpoint B — Obesity Management Review

• BMI calculated with percentile and extended BMI (if ≥ 95th) documented
• BMI plotted on CDC growth chart with trend visible
• Comorbidity screening labs ordered or reviewed (lipids, glucose/HbA1c, ALT)
• Blood pressure measured and classified
• Dietary assessment documented with specific targets identified
• Physical activity and screen time assessed
• Sleep duration assessed
• Psychological screening completed (depression, bullying, disordered eating)
• Stage of intervention assigned with rationale
• SMART goals documented for this visit
• Follow-up visit scheduled at appropriate interval for stage
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Follow AAP 2023 Clinical Practice Guideline for Evaluation and Treatment of Children and Adolescents with Obesity
• Use CDC BMI-for-age growth charts (ages 2-20) with extended BMI percentiles for severe obesity classification
• Apply Expert Committee (Barlow 2007) staged approach for intervention intensity
• Follow NHLBI Integrated Guidelines for Cardiovascular Health (lipid screening schedule)
• Follow ADA Standards of Care for T2DM screening criteria in youth
• Follow NASPGHAN guidelines for NAFLD screening in children
• GLP-1 RA therapy: follow FDA-approved labeling (liraglutide and semaglutide ≥ 12 years)
• Metabolic surgery: follow ASMBS pediatric guidelines; accredited center required
• Do not use BMI in children under 2 — use weight-for-length on WHO growth chart
• Avoid stigmatizing language: use "has obesity" not "is obese"; use "unhealthy weight" not "fat"
• This skill produces clinical documentation; it does not replace clinical judgment